Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2596)	9/22/2009 11:49:09 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

BSDM opened with a good UG and is still up 130% with volume now > 6,410,000 bigcharts.marketwatch.com It reported today at Europe’s largest cancer congress, ECCO15 – ESMO34,results of a PIII of its BSD-2000 Hyperthermia System, demonstrating that patients with high risk soft-tissue sarcomas were 30% more likely to be alive and cancer free almost 3 Yrs. after starting treatment if hyperthermia was added to their chemotherapy treatment. They said that the addition of the use of hyperthermia more than doubled the proportion of patients whose tumours responded to chemotherapy without increasing toxicity, and plan to exxplore its use in other types of cancer, instead of or in combination with radiation therapy."We believe it is likely to change the way many specialists treat these tumours." <g> The stock had been lingering at the $2 level since March, although there had been two previous spikes to the $3 level in April and May in spite of the reported larger losses in the last 3Qs. But the insiders hold around 40% and BSDM doesn't have significant LTD.<g> The stock has a good amount of resistance at the $4 to $5 level and it seems better to wait for it to close some of today's UG and the report of some improvement on the bottom line.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2596)	1/14/2010 12:16:52 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

CYTK seems to have found support at the $3 level.<g> The stock has been up > 5% and is still up 4.42% with volume of 124,500 still < half its ADV bigcharts.marketwatch.com On Monday it announced positive data from Part B of its PI of CK-2017357 in healthy volunteers, designed to assess the pharmacodynamic effects of CK-2017357 on skeletal muscle function after single oral doses of 250, 500, and 1000 mg, and to assess the relationship of the effects observed to the associated plasma concentrations of CK-2017357. It announced that CK-2017357 produced concentration-dependent, statistically significant increases versus placebo in the force developed by the tibialis anterior and that the doses administered were well tolerated by the healthy volunteers that participated. CK-2017357 is a fast skeletal muscle troponin activator and is its lead drug candidate from the company's skeletal sarcomere activator program. It selectively activates the fast skeletal troponin complex and increases its sensitivity to calcium, leading to an increase in skeletal muscle force. CYTK's skeletal muscle contractility program is focused to the discovery and development of small molecule skeletal sarcomere activators and leverages its ongoing discovery of cardiac sarcomere activators, including the cardiac myosin activator, omecamtiv mecarbil,which is in a PII for treatment of heart failure. Skeletal sarcomere activators have demonstrated pharmacological activity that may lead to new therapeutic options for diseases associated with aging, muscle wasting, and neuromuscular dysfunction. By directly improving skeletal muscle function, a small molecule activator of the skeletal sarcomere may potentially enhance physical performance and quality of life in aging patients and patients with ALS and cachexia. CYTK has 4Qs of better revenues and has been trimming its losses. The EL for the current Yr is around $0.40 vs. $1.09 in 2008 but for 2010 a loss around $0.75 is still projected <g> CYTK reportedly has relatively small LTD, small +CF and pretty good institutional following. With some good news it could get back to the $5 level.<g> bigcharts.marketwatch.com Bernard